Skip to content

Ultragenyx Pharmaceutical RARE Other Working Capital

Other Working Capital at other companies

Eli Lilly logo
Eli LillyLLY
-$175M-137%
Amgen logo
AmgenAMGN
$67M+34.0%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$7.63M+115%
Arrowhead Research logo
Arrowhead ResearchARWR
-$385K+78.2%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$8.8M-291%
Moderna logo
ModernaMRNA
-$6M-200%

Other financials

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total debt$36.0M-10.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation

See full
Market cap$2.83B-39.4%
P/S4.2×-3.7×

Profitability

See full
Gross margin97.2%
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×
Current ratio-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's other working capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's other working capital?
Ultragenyx Pharmaceutical (RARE) reported other working capital of -$1M in Q1 2026.
How has Ultragenyx Pharmaceutical's other working capital changed year-over-year?
Ultragenyx Pharmaceutical's other working capital decreased by 200.0% year-over-year, from $1M to -$1M.
What does other working capital mean?
Net change in working capital items not separately classified — a residual balancing item.